Lumacaftor monotherapy

Drug Profile

Lumacaftor monotherapy

Alternative Names: Corrector VX-809; VRT-826809; VX-809

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Benzodioxoles; Benzoic acids; Cyclopropanes; Pyridines; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for lumacaftor in USA and European Union (Vertex Pharmaceuticals form 10-K, filed in February 2017)
  • 21 Jul 2016 Biomarkers information updated
  • 06 Oct 2015 Discontinued - Phase-III for Cystic fibrosis in Canada, Belgium, Netherlands, Germany, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top